P4-16-05: A Randomized Phase 2 Study of a Loading Dose of Ibandronate in Patients with Bone Metastases from Breast Cancer.

Mapping Intimacies ◽

10.1158/0008-5472.sabcs11-p4-16-05 ◽

2011 ◽

Author(s):

DM Ritchie ◽

C Bray ◽

P Canney

Keyword(s):

Breast Cancer ◽

Bone Metastases ◽

Loading Dose ◽

Phase 2 ◽

Phase 2 Study ◽

Randomized Phase 2

Download Full-text

Abstract PD3-01: Results from KATE2, a randomized phase 2 study of atezolizumab (atezo)+trastuzumab emtansine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+ advanced breast cancer (BC)

10.1158/1538-7445.sabcs18-pd3-01 ◽

2019 ◽

Author(s):

LA Emens ◽

F Esteva ◽

M Beresford ◽

C Saura ◽

M De Laurentiis ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Advanced Breast ◽

Trastuzumab Emtansine ◽

Phase 2 ◽

Phase 2 Study ◽

Previously Treated ◽

Randomized Phase 2

Download Full-text

Randomized phase 2 study of abiraterone acetate (AA) with or without exemestane (E) in postmenopausal patients (pts) with estrogen receptor–positive (ER+) metastatic breast cancer (MBC).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.519 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 519-519 ◽

Author(s):

Joyce O'Shaughnessy ◽

Mario Campone ◽

Etienne Brain ◽

Patrick Neven ◽

Daniel F. Hayes ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Abiraterone Acetate ◽

Phase 2 ◽

Phase 2 Study ◽

Estrogen Receptor Positive ◽

Randomized Phase 2

Download Full-text

Metronomic treatment of vinorelbine with oral capecitabine is tolerable in the randomized Phase 2 study XeNa including patients with HER2 non-amplified metastatic breast cancer

Acta Oncologica ◽

10.1080/0284186x.2020.1851045 ◽

2020 ◽

pp. 1-8

Author(s):

Anne Sofie Brems-Eskildsen ◽

Søren Linnet ◽

Hella Danø ◽

Adam Luczak ◽

Peter Michael Vestlev ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Phase 2 ◽

Oral Capecitabine ◽

Phase 2 Study ◽

Metronomic Treatment ◽

Randomized Phase 2

Download Full-text

Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18)

Breast Cancer Research and Treatment ◽

10.1007/s10549-020-05755-7 ◽

2020 ◽

Vol 183 (2) ◽

pp. 419-428 ◽

Author(s):

Richard S. Finn ◽

Katalin Boer ◽

Igor Bondarenko ◽

Ravindranath Patel ◽

Tamas Pinter ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Advanced Breast Cancer ◽

Advanced Breast ◽

Line Treatment ◽

Phase 2 ◽

Phase 2 Study ◽

Randomized Phase 2 ◽

First Line Treatment

Download Full-text

Abstract 4718: A randomized phase 2 study of the cyclin-dependent kinase (CDK) inhibitor dinaciclib (SCH 727965) in patients with advanced breast cancer

10.1158/1538-7445.am2011-4718 ◽

2011 ◽

Author(s):

Monica Mita ◽

Anil A. Joy ◽

Alain Mita ◽

Kamalesh Sankhala ◽

Jennifer Moseley ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Advanced Breast ◽

Cdk Inhibitor ◽

Phase 2 ◽

Cyclin Dependent Kinase ◽

Phase 2 Study ◽

Randomized Phase 2

Download Full-text

Abstract S2-05: Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) withBRCA1orBRCA2mutations and metastatic breast cancer: A randomized, phase 2 study

10.1158/1538-7445.sabcs16-s2-05 ◽

2017 ◽

Author(s):

HS Han ◽

V Diéras ◽

ME Robson ◽

M Palácová ◽

PK Marcom ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Phase 2 ◽

Phase 2 Study ◽

Randomized Phase 2

Download Full-text

Abstract P5-14-05: The impact of food on tolerability of abemaciclib in patients with previously treated hormone receptor-positive, HER2-negative, metastatic breast cancer: An open-label, randomized phase 2 study

10.1158/1538-7445.sabcs19-p5-14-05 ◽

2020 ◽

Author(s):

Elgene Lim ◽

Frances Boyle ◽

Meena Okera ◽

Sherene Loi ◽

Sema Sezgin Goksu ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Phase 2 ◽

Hormone Receptor Positive ◽

Phase 2 Study ◽

Previously Treated ◽

Randomized Phase 2

Download Full-text

Neoadjuvant therapy with trastuzumab emtansine and pertuzumab in patients with HER2-positive primary breast cancer (A randomized, phase 2 study; JBCRG-20)

Annals of Oncology ◽

10.1093/annonc/mdx362.010 ◽

2017 ◽

Vol 28 ◽

pp. v47-v48

Author(s):

N. Masuda ◽

S. Ohtani ◽

T. Takano ◽

K. Inoue ◽

E. Suzuki ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Therapy ◽

Primary Breast Cancer ◽

Trastuzumab Emtansine ◽

Phase 2 ◽

Her2 Positive ◽

Phase 2 Study ◽

Randomized Phase 2

Download Full-text

Abstract PD1-01: Open-label, randomized, phase 2 study of sapanisertib (TAK-228/MLN0128) in combination with fulvestrant in postmenopausal women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor-2-negative (HER2-) advanced or metastatic breast cancer (MBC) that previously progressed during or after aromatase inhibitor therapy (NCT02756364)

10.1158/1538-7445.sabcs20-pd1-01 ◽

2021 ◽

Author(s):

José Á García-Saenz ◽

Noelia Martínez Jáñez ◽

Miguel Martin ◽

Ainhara Lahuerta Martínez ◽

Santiago González-Santiago ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Phase 2 ◽

Aromatase Inhibitor Therapy ◽

Phase 2 Study ◽

Estrogen Receptor Positive ◽

Epidermal Growth ◽

Randomized Phase 2

Download Full-text

Abstract PD14-09: Nci 10013 - A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel, with or without atezolizumab in triple negative breast cancer (TNBC)

10.1158/1538-7445.sabcs20-pd14-09 ◽

2021 ◽

Author(s):

Foluso O Ademuyiwa ◽

Feng Gao ◽

Ina Chen ◽

Donald W Northfelt ◽

Robert Wesolowski ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Phase 2 ◽

Phase 2 Study ◽

Randomized Phase 2

Download Full-text